ERBB2 and breast carcinoma: Additionally, recent advancements in adjuvant ET, particularly with the development of oral selective estrogen receptor degraders (SERDs), as investigated in the EMBER-433 and CAMBRIA-134 trials, offer promising alternatives for patients with ER-positive, ERBB2-negative breast cancer.